Several genome-wide transcription profiling studies have demonstrated high EPHA4 expression in Sézary syndrome (SS), a leukemic variant of cutaneous CD4+ T-cell lymphoma (CTCL) with an aggressive clinical course and poor prognosis. This evidence concerns the gene EPHA4 and primary cutaneous T-cell non-Hodgkin lymphoma.